Since, the majority of KIT–dependent and–independent mutant clones activate the PI3K/MAPK pathways, we hypothesized that inhibiting the PI3K/MAPK pathways together with KIT inhibition could be a potential therapy for IM/SU/RE–refractory GIST. The gene discussed is PIK3CA; the disease is gastrointestinal stromal tumor.